mRNA Vaccines and Therapeutics Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on MRNA Vaccines and Therapeutics Market 

5.1. COVID-19 Landscape: MRNA Vaccines and Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global MRNA Vaccines and Therapeutics Market, By Disease Type

8.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by Disease Type, 2024-2033

8.1.1 Hereditary Transthyretin-mediated Amyloidosis Genetic

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Acute Hepatic Porphyria

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Primary Hyperoxaluria Type 1

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Atherosclerotic Cardiovascular Disease

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global MRNA Vaccines and Therapeutics Market, By Route of Administration

9.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by Route of Administration, 2024-2033

9.1.1. IV Infusion

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Subcutaneous

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global MRNA Vaccines and Therapeutics Market, By End-user Type 

10.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by End-user Type, 2024-2033

10.1.1. Research Institutes

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Hospitals and Clinics

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global MRNA Vaccines and Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Disease Type (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by End-user Type (2021-2033)

Chapter 12. Company Profiles

12.1. Kernal Biologics Inc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Sanofi

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Argos Therapeutics Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Charoen Pokphand Group

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AIM Vaccine Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. CureVac SE

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Ethris GmbH

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bohringer Ingelheim International GmbH

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Arcturus

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Daiichi Sankyo

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms